Human immunodeficiency virus (HIV) enters target cells by specific interactions between the viral envelope proteins gp41 and gp120 and human target cell receptors. The long term goal of this project is to discover small, drug-like, molecules that disrupt HIV entry by binding to viral envelope or human target cell receptor proteins.
The specific aims are:
Specific Aim 1 : Develop the pseudo typing assay of HIV envelope-mediated viral entry for application to high throughput screening (HTS) of small drug-like molecules by robotic systems.
Specific Aim 2 : Extend the HIV entry assay for discrimination between small molecule inhibitors that bind to HIV envelope proteins, from small molecule inhibitors that bind to human target receptor proteins.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Small Research Grants (R03)
Project #
1R03NS053753-01
Application #
7021829
Study Section
Special Emphasis Panel (ZNS1-SRB-G (01))
Program Officer
Scheideler, Mark A
Project Start
2005-09-30
Project End
2007-08-31
Budget Start
2005-09-30
Budget End
2007-08-31
Support Year
1
Fiscal Year
2005
Total Cost
$77,500
Indirect Cost
Name
University of Illinois at Chicago
Department
Biochemistry
Type
Schools of Medicine
DUNS #
098987217
City
Chicago
State
IL
Country
United States
Zip Code
60612
Guo, Ying; Tisoncik, Jennifer; McReynolds, Susanna et al. (2009) Identification of a new region of SARS-CoV S protein critical for viral entry. J Mol Biol 394:600-5